close
menu
close
menu
close
menu
close
menu
01/04/2025 – Diagnexia, a global leader in AI-powered digital pathology, and Stratipath AB, a pioneer in AI-based cancer diagnostics, are pleased to announce a strategic partnership. This collaboration will bring Stratipath Breast, an AI-based prognostic risk profiling tool for invasive breast cancer, to pathology laboratories, hospitals, and healthcare providers across the UK and Europe. By integrating Stratipath’s AI-based technology into Diagnexia’s digital pathology network, the partnership will enable faster, more precise, and cost-effective cancer diagnostics, benefiting both clinicians and patients by enabling faster, more precise treatment decisions.
Stratipath Breast is an AI-based prognostic tool that analyses routine H&E-stained histopathology images to classify breast cancer tumors into high- and low-risk categories. The solution is compliant for clinical use in the EU and UK (CE-IVD and UK Rep), and is already in clinical use in several hospitals. This approach provides rapid and actionable insights, enabling oncologists and pathologists to:
While gene expression tests provide valuable insights for treatment decisions, their high costs, lengthy turnaround times, and complex handling limit accessibility and contribute to unequal access to precision diagnostics. Stratipath Breast simplifies this process by analysing routine pathology HE slides already in the diagnostic workflow. With no additional investment or manual handling required, it enables faster, more efficient, and equitable access to precision diagnostics.
As a leader in digital and computational pathology, Diagnexia connects a global network of subspecialty pathologists with hospitals and laboratories. This partnership aligns with Diagnexia’s mission to enhance diagnostic efficiency, accuracy, and accessibility through cutting-edge AI tools.
By including Stratipath Breast into its state-of-the-art digital pathology platform, Diagnexia will:
This partnership aligns with Diagnexia’s mission to improve efficiency, accuracy, and accessibility in cancer diagnostics, ultimately leading to better patient outcomes.
“Stratipath Breast is a natural addition to our portfolio of AI-Based digital pathology solutions. At Diagnexia, we are committed to advancing precision oncology by integrating AI into routine clinical workflows. This partnership allows us to bring Stratipath’s groundbreaking risk stratification technology to more patients and clinicians, reducing delays and improving access to personalised cancer diagnostics.” said Donal O'Shea, CEO of Diagnexia
“This partnership with Diagnexia marks a major step in expanding access to AI-based prognostic risk profiling across the UK and Europe. By leveraging AI, more oncologists will have access to faster and more affordable risk stratification tools, enabling quicker treatment decisions and reducing the need for costly gene expression tests,” said Fredrik Wetterhall, CEO of Stratipath
This partnership between Diagnexia and Stratipath represents a milestone in the adoption of AI-based oncology solutions. By shortening turnaround times, reducing costs, and improving diagnostic precision, this collaboration will expand access to life-saving prognostic insights for breast cancer patients across the UK.
The Stratipath Breast AI-based prognostic test, will soon be offered by Diagnexia, providing clinicians across the UK with a cutting-edge AI solution for breast cancer risk stratification and precision diagnostics.
Stratipath is an AI company dedicated to revolutionising cancer treatment decisions and enhancing patient outcomes by assisting physicians in delivering optimal treatment to every patient. Stratipath’s pioneering solutions and AI-based precision diagnostic software platform transform tissue sample analysis, enabling breakthrough insights for enhanced and faster patient stratification across healthcare, clinical trials, and drug development. By expanding the reach of precision medicine, Stratipath aims to make this advanced healthcare approach accessible to a wider patient population. Founded as a spin-out of Karolinska Institutet in Stockholm, Sweden, Stratipath is built upon years of groundbreaking research and development.
For more information, please visit www.stratipath.com.
Diagnexia is a global leader in digital pathology, offering expert diagnostic services supported by advanced AI tools and a global network of subspecialty pathologists. With state-of-the-art facilities in Oxford and Exeter, Diagnexia is committed to transforming patient care through innovation and technology.
For more information, please visit www.diagnexia.com
01/04/2025 – Diagnexia, a global leader in AI-powered digital pathology, and Stratipath AB, a pioneer in AI-based cancer diagnostics, are pleased to announce a strategic partnership. This collaboration will bring Stratipath Breast, an AI-based prognostic risk profiling tool for invasive breast cancer, to pathology laboratories, hospitals, and healthcare providers across the UK and Europe. By integrating Stratipath’s AI-based technology into Diagnexia’s digital pathology network, the partnership will enable faster, more precise, and cost-effective cancer diagnostics, benefiting both clinicians and patients by enabling faster, more precise treatment decisions.
Stratipath Breast is an AI-based prognostic tool that analyses routine H&E-stained histopathology images to classify breast cancer tumors into high- and low-risk categories. The solution is compliant for clinical use in the EU and UK (CE-IVD and UK Rep), and is already in clinical use in several hospitals. This approach provides rapid and actionable insights, enabling oncologists and pathologists to:
While gene expression tests provide valuable insights for treatment decisions, their high costs, lengthy turnaround times, and complex handling limit accessibility and contribute to unequal access to precision diagnostics. Stratipath Breast simplifies this process by analysing routine pathology HE slides already in the diagnostic workflow. With no additional investment or manual handling required, it enables faster, more efficient, and equitable access to precision diagnostics.
As a leader in digital and computational pathology, Diagnexia connects a global network of subspecialty pathologists with hospitals and laboratories. This partnership aligns with Diagnexia’s mission to enhance diagnostic efficiency, accuracy, and accessibility through cutting-edge AI tools.
By including Stratipath Breast into its state-of-the-art digital pathology platform, Diagnexia will:
This partnership aligns with Diagnexia’s mission to improve efficiency, accuracy, and accessibility in cancer diagnostics, ultimately leading to better patient outcomes.
“Stratipath Breast is a natural addition to our portfolio of AI-Based digital pathology solutions. At Diagnexia, we are committed to advancing precision oncology by integrating AI into routine clinical workflows. This partnership allows us to bring Stratipath’s groundbreaking risk stratification technology to more patients and clinicians, reducing delays and improving access to personalised cancer diagnostics.” said Donal O'Shea, CEO of Diagnexia
“This partnership with Diagnexia marks a major step in expanding access to AI-based prognostic risk profiling across the UK and Europe. By leveraging AI, more oncologists will have access to faster and more affordable risk stratification tools, enabling quicker treatment decisions and reducing the need for costly gene expression tests,” said Fredrik Wetterhall, CEO of Stratipath
This partnership between Diagnexia and Stratipath represents a milestone in the adoption of AI-based oncology solutions. By shortening turnaround times, reducing costs, and improving diagnostic precision, this collaboration will expand access to life-saving prognostic insights for breast cancer patients across the UK.
The Stratipath Breast AI-based prognostic test, will soon be offered by Diagnexia, providing clinicians across the UK with a cutting-edge AI solution for breast cancer risk stratification and precision diagnostics.
Stratipath is an AI company dedicated to revolutionising cancer treatment decisions and enhancing patient outcomes by assisting physicians in delivering optimal treatment to every patient. Stratipath’s pioneering solutions and AI-based precision diagnostic software platform transform tissue sample analysis, enabling breakthrough insights for enhanced and faster patient stratification across healthcare, clinical trials, and drug development. By expanding the reach of precision medicine, Stratipath aims to make this advanced healthcare approach accessible to a wider patient population. Founded as a spin-out of Karolinska Institutet in Stockholm, Sweden, Stratipath is built upon years of groundbreaking research and development.
For more information, please visit www.stratipath.com.
Diagnexia is a global leader in digital pathology, offering expert diagnostic services supported by advanced AI tools and a global network of subspecialty pathologists. With state-of-the-art facilities in Oxford and Exeter, Diagnexia is committed to transforming patient care through innovation and technology.
For more information, please visit www.diagnexia.com
